U.S. Pharmacist Weekly News

May 22, 2024

Limiting Weight Gain After Discontinuing Smaller-Dose Semaglutide

Is weight gain inevitable after discontinuation of semaglutide? A new study suggests it does not have to be. Find out how patients involved in a weight-loss program were able to taper off the drug more effectively while managing weight gain and how they achieved the desired effects with smaller-than-normal dosages of semaglutide.

What’s Behind Sildenafil Dose Changes for PAH?

Pharmacists have recently been seeing different sildenafil dosages prescribed for pulmonary arterial hypertension (PAH), and many are unaware of the reason for the changes. A new study published in Circulation describes how the FDA changed recommendations based on a study of the correlation between various sildenafil doses and mortality in adults with PAH. Read more.

Mail-Order Pharmacy Dispensing of Mifepristone Appears Safe, Effective

Dispensing mifepristone by mail from certified pharmacies appears to be safe and effective, according to a new study. The public health decision 3 years ago to no longer require in-person dispensing was controversial, but researchers now find high patient satisfaction and very few adverse effects in the more than 500 women studied. Read more.

Hypoglycemia Risks Lower for Second-Generation Basal Insulin in T2D

The risk of hypoglycemia is relatively low in type 2 diabetes (T2D) patients injecting basal insulin once or twice a day, especially if they use some of the newer formulations. Learn more about results from a study that was performed to help address hypothetical future concerns about hypoglycemia risks with once-weekly basal insulins.